A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study.
James I. Geller
No relevant relationships to disclose
John Peter Perentesis
No relevant relationships to disclose
Charlotte H. Ahern
No relevant relationships to disclose
Rachel A. Kudgus
No relevant relationships to disclose
Elizabeth Fox
No relevant relationships to disclose
Susan Blaney
No relevant relationships to disclose
Brenda Weigel
No relevant relationships to disclose